A Study of Donanemab Versus Placebo in Chinese Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening.
• A Telephone Interview for Cognitive Status - Modified (TICS-M) score indicative of intact cognitive function (cut-off score of 35 or higher)
• Clinical Dementia Rating-Global Score (CDR-GS) of 0
• A plasma P-tau result consistent with amyloid pathology
• A reliable study partner who:
‣ Provides written informed consent to participate in the study in their role
⁃ Has frequent contact with the participant and is familiar with their overall function and behavior, including daily activities and cognitive abilities
⁃ Is of legal age (18 years of age or older) to consent
⁃ Is available to conduct functional scales
• Have adequate literacy, vision, and hearing for neuropsychological testing